Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 8, 2013, Pages 504-509

  Zou, Jian Jun ^a   Fan, Hong Wei ^a   Chen, Shao Liang ^a   Tan, Jie ^a   He, Bang Shun ^a   Xie, Hong Guang ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ABCC3; Clopidogrel; CYP2C19; Multidrug resistance protein 3; Percutaneous coronary intervention; Pharmacogenomics; Platelet aggregation; Polymorphism; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL;

ABCC3 GENE; ADULT; ALLELE; ARTICLE; CHINESE; CORONARY STENT; DRUG EFFECT; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PERCUTANEOUS CORONARY INTERVENTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

EID: 84881007767     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12118     Document Type: Article

References (25)

1. Scheffer GL, Kool M, de Haas M et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 2002; 82: 193-201.
2. Zou JJ, Xie HG, Chen SL et al. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur. J. Clin. Pharmacol. 2013; 69: 771-7.
3. Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999; 29: 1156-63.
4. Chandra P, Zhang P, Brouwer KL. Short-term regulation of multidrug resistance-associated protein 3 in rat and human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 288: G1252-8.
5. Smith DA, Dalvie D. Why do metabolites circulate? Xenobiotica 2012; 42: 107-26.
6. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, Sugiyama Y. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J. Pharmacol. Exp. Ther. 2008; 327: 465-73.
7. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998; 433: 149-52.
8. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1-5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 2005; 33: 219-24.
9. Cao X, Gibbs ST, Fang L et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 2006; 23: 1675-86.
10. Kitamura Y, Kusuhara H, Sugiyama Y. Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine. J. Pharmacol. Exp. Ther. 2010; 332: 659-66.
11. Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet. Genomics 2008; 18: 823-33.
12. Lang T, Hitzl M, Burk O et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004; 14: 155-64.
13. Saito S, Iida A, Sekine A et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J. Hum. Genet. 2002; 47: 147-71.
14. Sasaki T, Hirota T, Ryokai Y et al. Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function. Drug Metab. Pharmacokinet. 2011; 26: 374-86.
15. Fukushima-Uesaka H, Saito Y, Maekawa K et al. Genetic variations of the ABC transporter gene ABCC3 in a Japanese population. Drug Metab. Pharmacokinet. 2007; 22: 129-35.
16. Hitzl M, Klein K, Zanger UM et al. Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J. Pharmacol. Exp. Ther. 2003; 304: 524-30.
17. Ansari M, Sauty G, Labuda M et al. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2012; 12: 386-94.
18. Xie HG, Zou JJ, Hu ZY, Zhang JJ, Ye F, Chen SL. Individual variability in the disposition of and response to clopidogrel. Pharmacogenomics and beyond. Pharmacol. Ther. 2011; 129: 267-89.
19. Luchessi AD, Silbiger VN, Cerda A et al. Increased clopidogrel response is associated with ABCC3 expression: A pilot study. Clin. Chim. Acta 2012; 413: 417-21.
20. Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 2007; 115: 708-16.
21. Cutlip DE, Windecker S, Mehran R. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-51.
22. Mauri L, Hsieh WH, Massaro JM. Stent thrombosis in randomized clinical trials of drug-eluting students. N. Engl. J. Med. 2007; 356: 1020-9.
23. Chen SL, Santoso T, Zhang JJA. randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions. J. Am. Coll. Cardiol. 2011; 57: 914-20.
24. Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci. 2007; 80: 1490-4.
25. Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D. In acute leukemia, the polymorphism -211C>T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene. Pharmacogenet. Genomics 2006; 16: 149-50.